Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $17.00 target price on the biopharmaceutical company’s stock.
Palatin Technologies Trading Up 2.9 %
PTN opened at $1.08 on Thursday. The stock has a market capitalization of $21.11 million, a PE ratio of -0.52 and a beta of 0.99. Palatin Technologies has a 12 month low of $0.68 and a 12 month high of $5.65.
Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) last released its quarterly earnings data on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) EPS for the quarter. On average, analysts predict that Palatin Technologies will post -2.03 earnings per share for the current year.
Institutional Trading of Palatin Technologies
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Recommended Stories
- Five stocks we like better than Palatin Technologies
- Do ETFs Pay Dividends? What You Need to Know
- Goldman’s Lost Decade Forecast: These 3 Growth Stocks Can Win
- What Are Some of the Best Large-Cap Stocks to Buy?
- WD-40 Company Gears Up for a Double-Digit Stock Advance
- Buy P&G Now, Before It Sets A New All-Time High
- Monster and Celsius Energized: Which Stock Offers More Upside?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.